Laigo Bio has raised €11.5 million in seed financing and appointed Matthew Baker as CEO to accelerate its SureTAC precision membrane protein degradation platform in oncology and immunology, including programs in autoimmune disease and graft rejection. The round was co-led by Kurma Partners and Curie Capital, with participation from Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons. The company plans to drive its oncology assets—targeting PD-L1, VEGF, and a Wnt pathway receptor—through preclinical development before partnering, while advancing three immunology candidates toward selection.
The editorial question is whether extracellular targeted protein degradation can deliver a step-change over antibody blockade in crowded categories and unlock “undruggable” membrane targets at scale. Antibody-based therapies neutralize activity; degraders aim to remove the protein altogether, potentially yielding deeper and more durable pathway suppression. Laigo’s approach uses bispecific antibodies to recruit a cell-surface E3 ligase and trigger ubiquitination and lysosomal clearance of the target. If this mechanism generalizes across tissues and targets with acceptable safety, it could pressure established biologic franchises and create new entry points where small molecules and classic antibodies have failed.
This matters now because protein degradation is pivoting from intracellular PROTACs toward the cell surface, where many validated and refractory targets reside. The scientific promise is tangible: degrading PD-L1 may offer a path to overcome resistance seen with checkpoint blockade, degrading VEGF could alter anti-angiogenic dynamics, and tackling Wnt receptors addresses a pathway with chronic tractability challenges. For patients, the proposition is deeper suppression without continuous high-level receptor engagement. For payers, claims of tissue selectivity and sparing of desirable cell functions hint at improved tolerability and potentially lower downstream resource use, but will require rigorous comparative and pharmacoeconomic evidence. For HCPs, Medical Affairs will need to define where degradation changes clinical decision-making versus standard-of-care antibodies, especially in ICI-refractory settings, transplant medicine, and autoimmune flares where on-target off-tissue effects have historically limited innovation.
Commercially, Laigo is signaling a partner-first model post-preclinical in oncology, which aligns with pharma appetite for de-risked platform assets. Differentiation will hinge on quantifiable depth and duration of target removal, activity in resistant populations, combinability with existing regimens, and manufacturability of bispecific formats at scale. Head-to-head or well-matched indirect comparisons against PD-(L)1 and anti-VEGF incumbents, as well as mechanistic biomarkers of degradation and downstream pathway modulation, will be critical to secure premium pricing and access. In immunology and graft rejection, target choice and tissue localization may offer clearer white space and faster clinical signal, but safety margins and immunogenicity management will define the ceiling.
Strategically, the investor syndicate reflects a European playbook that blends venture studios and translation funds with growth capital to industrialize academic science. With AbTAC- and LYTAC-like concepts moving from journals into pipelines, competition is shifting to the selection of druggable surface E3 ligases, control of internalization kinetics, and intellectual property around ligase–target pairs. Large pharma business development teams are likely to benchmark Laigo’s ligase toolbox, breadth of disease-relevant targets, and CMC readiness alongside early in vivo efficacy.
The next 12–18 months will tell whether extracellular degraders can produce a first, clean clinical signal that justifies displacement of entrenched biologics. The strategic question for Laigo is where to claim first proof: a high-visibility but crowded PD-L1 path, or a less contested autoimmune or transplant niche that could validate the platform with clearer clinical differentiation and payer receptivity.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
